Prudentia Sciences, an AI-powered technology platform for life sciences, emerged from stealth this week supported by $7 million in funding! Learn more about the Wilson Sonsini team that advised Prudentia on the transaction, led by Mark Solakian, Tamara Labanowski, and Aaron Gordon, at: https://lnkd.in/gMg_9vre
Exciting News: Prudentia Sciences Launches with $7M in Funding to Revolutionize Life Sciences Dealmaking! We are thrilled to announce the public launch of Prudentia Sciences, a cutting-edge AI-powered technology platform designed to accelerate drug pipelines, optimize capital allocation, and transform how biopharma companies and investors approach asset diligence and valuation. With $7 million in seed funding led by GV (Google Ventures), with participation from Iaso Ventures and Virtue, we are poised to empower decision-makers across the life sciences sector to make faster, more informed, and data-driven dealmaking. Prudentia was purpose-built to fill a key market gap: Prudentia's AI-driven software platform helps biopharma and investors accelerate drug pipelines and maximize return on investment. Big shout out and congratulations to the Prudentia team! We also want to share a deep appreciation for our advisors, supporters and investors, particularly Wasim Malik, Anthony Philippakis, Crystal Huang, Raymond Sanchez, M.D., Travis May, Sean Doolan, Emre Karatas, Stuart Chaffee, Matthew Leoni, MD, MBA, Josef von Rickenbach, Mark Currie, Jennifer Byrne, Dan Burton. #LifeSciences #AI #Biopharma #Investment #Dealmaking #Startups #PrudentiaSciences #Funding Check out the full announcement here: